GlassScriptPhysician profile
Wally Nobleza Novero
NPI 1598752966
$4,961.89
in general payments reported to CMS, 2019-2025
18 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $549 · 2021: $1,238 · 2022: $600 · 2023: $217 · 2024: $340 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $965.79 | 2020-2025 | Caplyta |
| Alkermes, INC. | $743.42 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $637.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $534.38 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $470.86 | 2019-2023 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $407.91 | 2020-2022 | |
| Axsome Therapeutics, INC. | $374.86 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $217.70 | 2025 | Cobenfy |
| Lundbeck LLC | $156.21 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $113.09 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $112.36 | 2021-2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $82.50 | 2021 | |
| Neurocrine Biosciences, INC. | $71.18 | 2021-2022 | |
| Indivior INC. | $20.71 | 2021 | |
| Adlon Therapeutics L.P. | $15.18 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $13.47 | 2021 | |
| Bioxcel Therapeutics, INC. | $13.20 | 2023 | Igalmi |
| Neuronetics, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wally Novero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.